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Purpose: To report the prevalence of vitreomacular interface abnormality (VMIA) and the incidence of the
development of VMIA in patients with diabetic macular edema (DME). Factors associated with the
development of VMIA were also investigated.
Methods: This is a retrospective observational study. Patients with DME who were followed for at least 6
months were reviewed. Ophthalmoscopic examination, fundus photography, ﬂuorescein angiography,
and optical coherence tomography were used to detect DME and VMIA.
Results: A total of 244 eyes in 180 patients were found to have DME at the initial visit. Of these, 16 eyes
(6.56%) were also diagnosed with VMIA. Ninety-six eyes in 76 patients with DME who did not receive an
intravitreal operation or medications were included in the follow-up study. VMIA developed in 8 eyes
(8.33%) over a mean follow-up duration of 22.63 months, which corresponded to a calculated annual
incidence of 4.42%. The mean time from the initial visit to the detection of VMIA was 19 months. Older
age was found to be a risk factor for the development of VMIA. The occurrence of VMIA was associated
with worsening visual acuity and a thicker central retinal thickness on the ﬁnal visit.
Conclusion: This study reveals the prevalence of VMIA on the initial visit and the incidence and risk
factors associated with the occurrence of VMIA in patients with DME. This study also found that the
occurrence of VMIA was signiﬁcantly associated with poor visual outcomes and worsened macular
edema at the end of the observation period.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Diabetic retinopathy is one of the leading causes of blindness
worldwide, and diabetic macular edema (DME) is the most
important cause of visual loss in patients with diabetic retinop-
athy.1 A large population-based study, theWisconsin Epidemiologic
Study of Diabetic Retinopathy, reported that the incidence of DME
over the studied 10-year period was 20.1% in the young-onset
group, 25.4% in the old-onset group (which was taking insulin),
and 13.9% in the oldest-onset group (which was not taking
insulin).2 For years, macular laser photocoagulation has been the
standard treatment for DME. The Early Treatment of Diabetic
Retinopathy Study (ETDRS) reported that laser photocoagulationology, Shin Kong Wu Ho-Su
ih-Lin District, Taipei 11120,
.-K. Cheng).
e Ophthalmologic Society of Taiwsigniﬁcantly reduces the risk of moderate visual loss in patients
with clinically signiﬁcant macular edema.3 However, approxi-
mately 12% of treated patients still lost their vision.3 For diffuse
DME, the nonresponse rate to macular laser treatment was re-
ported to be 24.6% in a long-term study4; persistent macular edema
was believed to be the main cause of this unresponsiveness.3
Recently, vitreomacular interface abnormality (VMIA) has been
found to be associated with persistent DME that is unresponsive to
macular laser therapy.5e7
Clinically, VMIA is characterized by a highly reﬂective band over
the inner retinal surface at themacular area.7 It is deﬁned by optical
coherence tomography (OCT) as having the features of epiretinal
membrane (ERM) and/or anomalous vitreomacular adhesions.6e8
The latter is sometimes referred to as posterior vitreomacular
separation,9 posterior hyaloid traction,5 or vitreomacular traction7
in the literature and is characterized by ophthalmoscopic exami-
nation as having the features of a taut, thick posterior hyaloid.9 OCT
is generally regarded as superior to conventional fundus exami-
nation for the evaluation of the vitreomacular interface in order toan. Published by Elsevier Taiwan LLC. All rights reserved.
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patients with persistent DME, Ghazi et al found that OCT is 1.9
times more sensitive for the detection of VMIA than a combination
of biomicroscopic fundus examination, stereoscopic fundus
photography, and ﬂuorescein angiography (FA).6
Recently, vascular endothelial growth factor (VEGF) was shown
to be associated with the pathogenesis of diabetic retinopathy and
DME,12e14 and many clinical studies have also revealed the bene-
ﬁcial effects of intravitreal injection of anti-VEGF antibodies such as
bevacizumab and ranibizumab for both reducing macular edema
and improving visual acuity in patients with DME.15e20 In a large-
scale, randomized, controlled trial, intravitreal anti-VEGF injec-
tionwas found to be superior tomacular grid laser therapy in terms
of 1- and 2-year clinical outcome measurements.19,20 However, in
a recent study, Wu et al revealed that even with anti-VEGF treat-
ment, DME and the features of VMIA may be associated with poor
clinical results.21 On the other hand, growing evidence suggests
that vitrectomy with the induction of posterior hyaloid separation
and the release of the tractional membrane might provide beneﬁ-
cial effects for the treatment of persistent DME in association with
VMIA.22 Therefore, determining the features of VMIA may provide
signiﬁcant clinical implications for the clinical management of
patients with DME. However, clinical studies exploring the inci-
dence and the risk factors of VMIA formation in DME patients are
still very scarce in the literature.
In this study, we retrospectively investigated the incidence of
VMIA formation in a group of patients with clinically evident DME
who were regularly followed at our clinic for at least 6 months. The
prevalence of VMIA, as indicated by the OCT ﬁndings in all patients
with DME on the initial visit, was also recorded. Since July 2005, the
retinal clinic of our institute began to perform standardized
macular OCT examinations on all patients on their initial visit, in
addition to ophthalmoscopic examination and/or supplementary
fundus photography and FA. Patients with diabetic macular edema
should have OCT examinations performed at every scheduled visit.
The occurrence of VMIA in patients with DME who regularly visit
our clinic could, thus, be recorded. We excluded patients who had
undergone intravitreal operations, such as vitrectomy or intra-
vitreal injection of anti-VEGF or corticosteroids, prior to or within 6
months of the observation. To better understand the conditions
associated with the formation of VMIA in DME patients, several
systemic and ocular factors, including age, sex, the presence of
hypertension and hyperlipidemia, mean level of glycosylated
hemoglobin (HbA1c), baseline refractive status, best-corrected
visual acuity (BCVA), central retinal thickness (CRT), and history
of cataract surgery, macular laser treatment, and pan-retinal
photocoagulation (PRP) were further analyzed to determine any
correlations. We hope that this report may help ophthalmologists
better understand the prevalence, incidence, and risk factors for the
formation of VMIA in patients with DME.
2. Patients and methods
We conducted a retrospective study of patients with DME who
were treated at Shin Kong Wu Ho-Su Memorial Hospital (Taipei,
Taiwan) fromMarch 2006 through January 2010. Approval from the
institutional review board and ethics committee was obtained. The
clinical records of all consecutive patients with DME were
reviewed. The diagnosis of DME was made by the presence of
exudative changes and the thickening of the macular area on the
ophthalmoscopic examination and evidence of late macular
leakage on FA. Increased CRT, cystic changes, and subretinal ﬂuid
might also have been found on the OCT examination. Because
different combinations of these features were often found in the
same patients, we did not classify our patients according to the FAor OCT patterns that were noted in this study. Eyes with evidence of
VMIA on the initial visit were recorded. Eligible patients were
enrolled in this study according to the inclusion and exclusion
criteria. The inclusion criteria for our study included an initial
diagnosis of DME without VMIA by ophthalmoscopy, FA, or OCT
with regular follow-up for at least 6 months after the ﬁrst diag-
nosis of DME. Patients were excluded if they had any of the
following conditions: (1) regular follow-up <6 months; (2) VMIA
or vitreous hemorrhage on the initial visit; (3) vitrectomy prior to
or within 6 months of the follow-up period; (4) intravitreal anti-
VEGF or corticosteroid injection prior to or within 6 months of
the follow-up period; (5) vitreous hemorrhage that precluded
a detailed macular examination within 6 months of the follow-up
period; and (6) concomitant ocular diseases such as posterior
uveitis, advanced age-related macular degeneration, or retinal
vascular occlusions. If a vitrectomy or intravitreal injection of anti-
VEGF or corticosteroids was administered to our patients during
the course of this study, data collection was terminated and the
follow-up period was considered until the last visit before surgery.
On the other hand, macular focal, grid laser, PRP, and cataract
operations before or during the follow-up period were recorded as
items for subsequent analysis.
Each patient underwent BCVAmeasurement using ETDRS charts
at a distance of 4 m and ophthalmic slit-lamp biomicroscopy on
each visit. Central retinal characteristics were analyzed using OCT
(Stratus III; Carl Zeiss, Dublin, CA, USA) that utilized six diagonal
6-mm radial line scans through a dilated pupil and the macular
thickness map program (versions 4.0). A macular thickness map
algorithm centered on the fovea was also performed. Patients were
regularly followed at 1w3-month intervals.
The OCT characteristics of VMIA were deﬁned as having the
features of ERM or anomalous vitreomacular adhesions.6,8 The OCT
conﬁgurations of ERM were deﬁned as partially separated or
globally adherent membranes above the macular area according to
the classiﬁcation reported by Wilkins et al.8 Partially separated
ERM may be detected as thin, but distinctive, highly reﬂective
bands just above the inner surface of the retina with some focally
attached points. Globally adherent membranes may be detected
when various combinations of the following conﬁgurations are
noted: macular pseudohole, difference in the optical reﬂectivity
between the membrane and retina, or a visible tuft or edge of the
membrane. Anomalous vitreomacular adhesion was deﬁned as an
evident hyperreﬂective band that adhered to the surface of the
retina at speciﬁc sites, was elevated elsewhere off of the surface,
and continuous with the posterior vitreous surface, in agreement
with the report by Ghazi et al.6 Ophthalmoscopic indications of
VMIA were deﬁned as either a ﬁne or glistening membrane over-
lying the macula or a thickened whitish tissue that induced wrin-
kling of the retinal surface and obscured the underlying vasculature
on ophthalmoscopic examination and fundus photography.
Torturous vessels with varying degrees of leakage might be present
on FA. Eyes were diagnosed with VMIA when an OCT conﬁguration
of ERM or anomalous vitreomacular adhesion was detected in at
least two of the six diagonal scans on the OCT examination together
with characteristic ﬁndings on the ophthalmoscopic examination,
fundus photography, or FA.
Systemic conditions, such as a history of hypertension, hyper-
lipidemia, macular grid, focal laser, and PRP and the level of HbA1c
were recorded on follow-up examinations. Diabetes mellitus was
diagnosed from a self-reported history of medications and/or
a fasting plasma glucose level 7.0 mmol/L or a 2-hour postloading
glucose level 11.1 mmol/L. Hypertension was deﬁned as systolic
blood pressure 140 mmHg, diastolic blood pressure 90 mmHg,
or the concurrent use of antihypertensive medication. Hyperlipid-
emia was deﬁned as total cholesterol 200 mg/dL, low-density
Table 1
Demographic characteristics.
Eyes (cases) 96 (76)
Sex (male/female) 34/42
Age (y)a 60.03  8.74
Hypertension 50 (65.8%)
Hyperlipidemia* 50 (79.37%)
HbA1c (%)a 8.56  1.72
Baseline refraction (diopters)a 0.46  2.44
Baseline BCVA (LogMAR)a 0.46  0.50
Baseline CRT (mm)a 246.88  75.66
Macular grid laser 19 (19.79%)
PRP 52 (54.17%)
Prior cataract surgery Surgery 5 (5.21%)
Follow-up period (mo)a 22.63  14.13
Time from diagnosis of DME to ERM development (mo)a 19.00  8.94
Total incidence of VMIA 8 (8.33%)
Annual incidence of VMIA 4.42%
BCVA ¼ best-corrected visual acuity; CRT ¼ central retinal thickness;
DME ¼ diabetic macular edema; VMIA ¼ vitreomacular interface abnormality;
PRP ¼ pan-retinal photocoagulation.
* Total number of patients with a known lipid proﬁle ¼ 63.
a Data are presented as the mean  standard deviation.
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Visual acuity was recorded in Snellen units and converted
to logarithm of minimal angle of resolution (LogMAR) units
for statistical analysis. The values are expressed as the mean 
standard deviation. The data collected at the initial visit were
deﬁned as baseline data; data from the last visit were deﬁned as the
ﬁnal data. We also recorded the number of eyes that had received
cataract surgery, macular grid or focal laser treatment, and PRP
before or during follow-up.
We compared the mean age, mean HbA1c during follow-up,
baseline refractive status, baseline BCVA, ﬁnal BCVA, baseline CRT,
ﬁnal CRT, and the follow-up duration using the independent
samples t test for patients who developed VMIA (VMIA [þ] group)
and patients who did not (VMIA [-] group). The paired t test was
used to compare baseline BCVA and CRT values with the ﬁnal BCVA
and CRT values, respectively, between the two groups. We also
compared sex and the proportion of patients with a history of
hypertension, hyperlipidemia, cataract surgery, macular laser, and
PRP between the two groups using the Fisher exact test. Stepwise
multiple logistic regressionwas also used to determine associations
between the binary dependent variable (presence of VMIA) and the
continuous and categorical independent variables, such as age,
hypertension, hyperlipidemia, mean HbA1c, baseline refraction,
cataract surgery, macular laser, PRP, baseline BCVA, and baseline
CRT. A p value <0.05 was considered statistically signiﬁcant.
Statistical analysis was performed using SPSS 11.0 software (SPSS
Inc., Chicago, IL, USA).3. Results
3.1. Prevalence of VMIA on the initial visit
A total of 244 eyes in 180 consecutive patients with DME
received complete standardized examinations on the initial visit at
our retinal clinic. Of these, 16 eyes (6.56%) were found to have
a preexisting VMIA that was found during the initial visit. These
eyes, together with another 132 eyes, were excluded from the study
according to the exclusion criteria. The remaining 96 eyes in 76
patients were included in the study when calculating the incidence
of developing a subsequent VMIA.Table 2
Basic characteristics of the eyes that developed and did not develop VMIA.
VMIA (-) VMIA (þ) p
Eyes (cases) 88 (70) 8 (6)
Male/Female 31/39 3/3 >0.99
Age a (y) 58.84  8.84 66.00  7.84 0.030
Hypertension (%) 50 (71.4%) 5 (83.3%) 0.531
Hyperlipidemia* (%) 50 (87.8%) 6 (100%) 0.363
HbA1ca (%) 8.63  1.49 7.87  1.29 0.167
Refractive statusa (diopters) 0.34  2.49 1.72  1.47 0.128
Baseline BCVA (LogMAR)a 0.47  0.52 0.41  0.25 0.734
Baseline CRT a (mm) 248.20  78.54 232.25  27.64 0.571
Macular grid laser (%) 16 (18.2%) 3 (37.5%) 0.405
PRP (%) 47 (53.4%) 5 (62.5%) 0.723
Cataract surgery (%) 11 (12.5%) 2 (25.0%) 0.295
Follow-up (mo)a 22.05  13.78 29.00  17.32 0.184
VMIA ¼ vitreomacular interface abnormality; VMIA (þ) ¼ eyes with VMIA forma-
tion; VMIA (-)¼ eyes without VMIA formation; BCVA¼ best-corrected visual acuity;
CRT ¼ central retinal thickness; PRP ¼ pan-retinal photocoagulation.
Analyzed using the independent-samples t test: age, refractive status, HbA1c, BCVA,
CRT; Fisher exact test: sex, hypertension, hyperlipidemia, macular laser, PRP and
cataract surgery.
* Total number of patients with a known lipid proﬁle ¼ 63.
a Data are presented as the mean  standard deviation.3.2. Demographic data
Demographic data of these patients are shown in Table 1.
Ninety-six eyes (76 patients) were included in the follow-up study.
The mean age was 60.03  8.74 years, and there were 34 male and
42 female patients. The mean follow-up durationwas 22.63 14.13
months. The number of patients with hypertension and hyperlip-
idemiawas 50 of 76 patients (65.79%) and 50 of 63 patients (78.9%),
respectively, of those who had a recorded blood lipid proﬁle. The
number of eyes that had received a cataract operation, macular
laser, or PRP prior to or during the follow-up period were 13
(14.8%), 19 (19.79%), or 52 (54.17%), respectively. The mean refrac-
tive status was 0.46  2.44 diopters. The mean HbA1c level was
8.58  1.72%.
The mean baseline BCVAwas 0.46 0.50 LogMAR units (Snellen
equivalent: 6/17.3), and the mean ﬁnal BCVA was 0.58  0.55
LogMAR units (Snellen equivalent: 6/22.8), but there was no
statistically signiﬁcant difference between the baseline and ﬁnal
BCVAvalues. Themean BCVA at baseline deteriorated to level of the
ﬁnal visit by þ0.11  0.56 LogMAR units. The baseline CRT was
246.88  75.66 mm, and the ﬁnal CRT was 256.13  73.58 mm. The
mean CRT from the baseline to the ﬁnal visit deterioratedby þ9.25  81.65 mm. There was also no statistically signiﬁcant
difference between the baseline and ﬁnal CRT (p ¼ 0.270).3.3. Incidence and factors associated with VMIA formation
The basic characteristics of the eyes that developed and did not
develop VMIA are shown in Table 2. Eight eyes (8.33%) developed
VMIA during the follow-up period (Table 1), of which seven eyes
were classiﬁed as ERM and one eye was classiﬁed as anomalous
vitreomacular adhesion on OCT (Fig.1). The calculatedmean annual
incidence of VMIA (rate of VMIA formation/follow-up duration)
was 4.42% per year (Table 1). The mean duration from the diagnosis
of DME to the detection of VMIA was 19.00  8.94 months.
We performed additional statistical analyses to determine the
associations between various systemic and ocular factors and VMIA
formation in both groups (Table 2). Univariate analysis revealed
that only age was associated with the development of VMIA in our
study (p ¼ 0.03). Stepwise logistic regression also revealed that
older age was the only risk factor associated with VMIA
formation (p ¼ 0.04; odds ratio ¼ 1.101; 95% conﬁdence
Fig. 1. Optical coherence tomography (OCT) demonstrating changes in diabetic macular edema in representative cases. A, B) OCT ﬁndings (A) before and (B) after the development
of the epiretinal membrane (arrows). C, D) OCT ﬁndings (C) before and (D) after the development of anomalous vitreomacular adhesion (arrows).
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hypertension, hyperlipidemia, HbA1c, refractive status, and history
of cataract operation, macular laser, and PRP, were not signiﬁcantly
associated with the formation of VMIA.
3.4. VMIA formation and ﬁnal outcomes
Our study also determined that VMIA formation was signiﬁ-
cantly associated with poor visual outcomes and thicker CRT at the
ﬁnal visit. Eyes that eventually developed VMIA demonstrated
signiﬁcant deterioration from the baseline to the ﬁnal BCVA value
(0.41  0.25 LogMAR units to 1.14  0.76 LogMAR units, p ¼ 0.034),
while eyes without VMIA formation did not demonstrate this
signiﬁcant deterioration (0.47  0.52 LogMAR units to 0.52  0.51
LogMAR units, p ¼ 0.30; Fig. 2A). The changes from the baseline to
the ﬁnal BCVA values were also signiﬁcantly different (p < 0.001)
between eyes with (deteriorated by þ0.73  0.79 LogMAR units)
and without VMIA formation (deteriorated by þ0.06  0.50 Log-
MAR units; Table 3). Similarly, the deterioration from the baseline
to the ﬁnal CRT level was statistically signiﬁcant in eyes with VMIA
formation (232.25  27.64 mm to 355.63  81.66 mm, p ¼ 0.012) but
not in eyes without VMIA formation (248.20  78.54 mm to
247.08 66.20 mm, p¼ 0.883; Fig. 2B). Changes from the baseline to
the ﬁnal CRT level were also signiﬁcantly different (p < 0.001)
between eyes with (þ123.38  104.45 mm) and without VMIA
formation (-1.13  71.38 mm; Table 3).
4. Discussion
Our study investigated the incidence of the development of
VMIA in patients with diabetic retinopathy over a relatively long
period of time, which, to the best of our knowledge, has rarely been
reported in the literature. In this study, eight (8.33%) of a total of 96
eyes developed VMIA over a mean follow-up period of 22.63
months, which corresponds to a mean annual incidence of 4.42%
per year. The mean duration between of the development of VMIA
and the ﬁrst visit was 19.0 months. Of these eight eyes that
developed VMIA, seven eyes (7.29%) were of the ERM conﬁguration
(Fig. 1A,B) and one (1.04%) demonstrated the features of anomalous
vitreomacular adhesion (Fig. 1C,D). During the initial period of
including patients in our study, 16 eyes were found to already havebeen diagnosed with VMIA (16 of 244 eyes; 6.56%); therefore, 6.56%
may represent the prevalence of VMIA in patients with DME who
visit our retinal clinic.
We do not know if the calculated annual incidence of 4.42% per
year for the occurrence of VMIA in our patients with DME is higher
than that of the general population or not. As mentioned above,
there are no reports on the incidence of VMIA in DME patients. A
large survey on the general population, the Blue Mountains Eye
Study, reported that the 5-year cumulative incidence of idiopathic
ERM formation is 5.3% in the ﬁrst eye and 13.5% in the second eye.
ERM could be regarded as a speciﬁc type of VMIA that demon-
strates the growth of ﬁbrous tissue. It seems that the incidence of
VMIA (which predominantly presents as the ERM conﬁguration) in
the DME patients in our study is higher than that reported in the
Blue Mountains Eye Study; however, because the study designs,
methodologies, objectives, settings, and number of cases were all
very different, it is difﬁcult to directly compare various studies.
Furthermore, our study used OCT in addition to ophthalmoscopic
examination, fundus photographs, and FA to detect VMIA. OCT has
been reported as more sensitive and superior for the detection of
ERM and VMIA than traditional methods.6 Studies that did not use
OCT for the detection of VMIA may have underestimated its prev-
alence. This is especially true for many large-scale epidemiological
studies such as the Blue Mountains Eye Study that investigated the
prevalence of ERM formation before the invention of OCT. As
a result, it is still inconclusivewhether or not the incidence of VMIA
in patients with DME is higher than that of the general population.
The prevalence of 6.56% for VMIA that was found during the
initial visit of our 244 patients with DME is within the range of ERM
reported by most epidemiological surveys of the general pop-
ulation (2.2e18.5% according to the different methodologies used
to study different racial and age groups in different studies).23e31 A
similar study performed by Thomas et al used OCT to detect VMIA,
reporting a prevalence of only 10% for VMIA among 140 patients
with DME who had been previously treated using macular laser
therapy.9 They concluded that VMIA in DME might not be as
prevalent as might be expected from the literature. Other studies,
however, have found that the prevalence of ERM and VMIA seem to
increase with the severity of DME.6,9,32,33 Ghazi et al speciﬁcally
investigated cases of persistent and clinically signiﬁcant DME that
were refractory to macular grid laser treatment, reporting that the
Fig. 2. A) Baseline best-corrected visual acuity (BCVA) and ﬁnal BCVA in eyes with or
without the formation of vitreomacular interface abnormalities (VMIA). B) Baseline
central retinal thickness (CRT) and ﬁnal CRT in eyes with or without VMIA formation.
Both the ﬁnal BCVA and CRT values were signiﬁcantly worse than the initial BCVA and
CRT values in the VMIA (þ) group. * p < 0.05 by the paired t test. VMIA (-) ¼ eyes
without VMIA formation; VMIA (þ) ¼ eyes with VMIA formation.
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respectively.33 In our study, the mean initial CRT was only 246.88
um, which is much less than the mean CRT of the patients in the
study performed by Ghazi et al (353.8 um). This might explain why
our patients did not demonstrate a higher prevalence of VMIA on
the initial visit.Table 3
Comparison of eyes with and without VMIA formation in the non-IVB group.
VMIA (-) VMIA (þ) p
BCVA change þ0.06  0.50 þ0.73  0.79 <0.001
CRT change -1.13  71.38 þ123.38  104.45 <0.001
VMIA (þ) ¼ eyes with VMIA formation; VMIA (-) ¼ eyes without VMIA formation;
BCVA ¼ best-corrected visual acuity; CRT ¼ central retinal thickness.
*p < 0.05 according to the independent-samples t test.Our study also investigated the possible risk factors associated
with the development of VMIA in DME patients. In the literature,
older age has been identiﬁed as the most consistent risk factor
associated with the formation of idiopathic ERM in many large
population-based studies.23e31 Our statistical analysis also found
that older age was a major risk factor associated with VMIA
formation in our DME patients according to both univariate anal-
ysis (p ¼ 0.03; Table 2) and stepwise logistic regression (p ¼ 0.04;
odds ratio ¼ 1.101; 95% conﬁdence interval: 1.004e1.207). This
suggests that eyes with DME are associated with similar risk factor
as those with idiopathic ERM.
In our study, although procedures such as cataract extraction
surgery, macular laser, and PRP were associated with the devel-
opment of VMIA, these differences did not reach a statistic level of
signiﬁcance (Table 2). In the literature, macular laser is not
consistently associated with VMIA9,33; however, cataract surgery
and thermal laser photocoagulation, such as PRP, are well-known
risk factors associated with a high prevalence of VMIA for-
mation.30,31,34e39 It is possible that our study size was too small to
have enough statistical power to detect categorized risk factors,
such as the percentage of patients with a history of cataract surgery
or PRP, for infrequent complications like VMIA. Other systemic and
ocular factors, such as hypertension, hyperlipidemia, level of
HbA1c, and baseline refractive status, were also investigated in this
study and found to have no signiﬁcant correlation with the devel-
opment of VMIA (Table 2). These factors were also less consistently
found to be associated with the formation of ERM in previous
epidemiological reports.23e31
Our study also shows that the formation of VMIA in eyes with
DME signiﬁcantly affected the visual outcome and CRT at the ﬁnal
visit. Although the initial BCVA and CRT values were not signiﬁ-
cantly different between the VMIA (þ) and VMIA (-) groups, the
ﬁnal BCVA and CRT values were signiﬁcantly different. In eyes
where no VMIA was noted, the BCVA and CRT values were not
signiﬁcantly different between the initial and ﬁnal visits. However,
in eyes that developed VMIA, the BCVA and CRT values both
signiﬁcantly deteriorated (both p< 0.001; Table 3 and Fig. 2). In fact,
several patients with VMIA eventually received pars plana vitrec-
tomy (PPV) or membrane peeling to treat the deterioration of visual
function. It is unknown if the formation of VMIA was the cause of
the deterioration of both BCVA and CRTor was a co-phenomenon in
eyes that deteriorated over the course of the follow-up period.
In summary, our study reveals that our patients with DME
demonstrated a cumulative incidence of 8.33% over a mean
follow-up period of 22.63 months (calculated annual incidence:
4.42%), which was correlated with age. This result may
contribute to better knowledge regarding the general clinical
course of DME patients who are not receiving intravitreal
injection of any medication. However, several limitations need to
be noted. First, the retrospective design essentially precludes the
strict control of all systemic and ocular variables. Second, we
intentionally excluded all patients who had received vitreor-
etinal surgery before or during the follow-up period, such as PPV
or intravitreal injection of anti-VEGF or corticosteroids. Because
the necessity of these procedures usually indicated active
proliferative disease or severe macular edema, the exclusion of
these cases might suggest that most patients in our study
represent a population of patients with relatively less severe
diabetic retinopathy. Therefore, caution should be taken when
applying our result to patients with active diabetic retinopathy
or severe DME. Also, the number of eyes enrolled in our study
was probably insufﬁcient for a statistical comparison of the
incidence of infrequent complications such as VMIA or ERM
formation. Further studies with prospective and large-scale
designs are needed to verify these conclusions.
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